How much funding has Icosavax raised?

Icosavax has raised $151.0M in total funding, most recently a Series B round.

Who are Icosavax's investors?

Icosavax's investors include Omega Funds, RA Capital Management, Viking Global, Janus Henderson Investors, Perceptive Advisors.

Where is Icosavax headquartered?

Icosavax is headquartered in Seattle, Washington, United States.

What industry is Icosavax in?

Icosavax operates in Biotech, Healthcare.

Icosavax

IPO

Seattle, United States · Founded 2018 · $151.0M raised

Biotech

Healthcare

Headquarters: Seattle, Washington
Founded: 2018
Business Model: B2B
Website: icosavax.com

Total Funding: $151.0M
Last Round: $100.0M Series BApr 2021
Rounds: 2

About

Icosavax was a clinical-stage biopharmaceutical company that developed next-generation vaccines using computationally designed virus-like particle (VLP) technology, originally spun out of the University of Washington Institute for Protein Design in 2018. The company's platform enabled the engineering of synthetic nanoparticles that closely mimic natural viruses to elicit potent immune responses, with lead programs targeting RSV and hMPV. Icosavax's VLP-based approach offered a differentiated alternative to mRNA and traditional vaccine modalities. The company was acquired by AstraZeneca in early 2024 for approximately $1.1 billion.

Summary

Icosavax is a Biotech company based in Seattle, United States, founded in 2018. It has raised $151.0M in total across 2 rounds, most recently a $100.0M Series B round in Apr 2021. Investors include Omega Funds, RA Capital Management and Viking Global.